title: The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
abstract: In recent years, increasing amounts of trial data have become available indicating the clinical efficacy of epidermal growth factor receptor (EGFR)-targeted antibody therapy in the management of advanced colorectal cancer (CRC). These trial data have consistently demonstrated the modest single-agent activity of these agents when given in the chemorefractory setting and the potential ability for EGFR-targeted agents to reverse chemoresistance when given in combination with cytotoxic chemotherapy agents. In this article, we review the clinical development of EGFR-targeted therapies and discuss their current role in the management of patients with previously treated advanced CRC.
authors.affiliation: Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Watkins
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D018849:Controlled Clinical Trials as Topic; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D000077544:Panitumumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab